We are live on
!
Find out more
PCM
Prelude Capital Management Portfolio holdings
AUM
$1.31B
1-Year Est. Return
62.02%
This Fund
S&P 500
This Quarter
Est. Return
+16.88%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.03B
AUM Growth
-$287M
(-22%)
Cap. Flow
-$398M
Cap. Flow
% of AUM
-38.68%
Top 10 Holdings %
Top 10 Hldgs %
14.04%
Holding
1,478
New
335
Increased
269
Reduced
346
Closed
503
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$12.3M |
| 2 |
Alphabet (Google) Class C
GOOG
|
+$10.9M |
| 3 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$10.4M |
| 4 |
Tesla
TSLA
|
+$9.96M |
| 5 |
NVIDIA
NVDA
|
+$8.73M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$10.4M |
| 2 |
Broadcom
AVGO
|
+$9.33M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$8.68M |
| 4 |
DESP
Despegar.com
DESP
|
+$7.15M |
| 5 |
Oracle
ORCL
|
+$6.74M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 18.86% |
| 2 | Consumer Discretionary | 12.74% |
| 3 | Healthcare | 12.34% |
| 4 | Communication Services | 10.34% |
| 5 | Industrials | 8.95% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
401
Grupo Cibest SA
CIB
$21.1B
| $566K | 0.06% |
+12,250
| New | +$509K |
|
402
Prologis
PLD
$133B
| $566K | 0.06% |
5,381
-6,478
| -55% | -$679K |
|
403
Dutch Bros
BROS
$9.26B
| $558K | 0.05% |
8,167
-1,278
| -14% | -$83.4K |
|
404
NextNav
NN
$2.23B
| $556K | 0.05% |
36,605
-6,609
| -15% | -$84.8K |
|
405
Corbus Pharmaceuticals
CRBP
$190M
| $554K | 0.05% |
80,347
| – | – |
|
406
Celanese
CE
$4.82B
| $553K | 0.05% |
+10,000
| New | +$498K |
|
407
Agree Realty
ADC
$9.41B
| $553K | 0.05% |
+7,570
| New | +$569K |
|
408
Terex
TEX
$7.74B
| $551K | 0.05% |
11,807
-2,292
| -16% | -$95.8K |
|
409
Crown Holdings
CCK
$13.1B
| $549K | 0.05% |
5,330
+2,833
| +113% | +$270K |
|
|
CTLP
410
DELISTED
Cantaloupe
CTLP
| $546K | 0.05% |
+49,675
| New | +$430K |
|
411
Target
TGT
$68B
| $546K | 0.05% |
+5,532
| New | +$531K |
|
412
BioCryst Pharmaceuticals
BCRX
$2.4B
| $546K | 0.05% |
60,897
-39,003
| -39% | -$363K |
|
413
Bank of America
BAC
$442B
| $542K | 0.05% |
11,445
+1,530
| +15% | +$64.4K |
|
414
Snap
SNAP
$9.01B
| $541K | 0.05% |
+62,300
| New | +$517K |
|
|
LKFT
415
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.77B
| $540K | 0.05% |
19,305
| – | – |
|
416
G-III Apparel Group
GIII
$1.5B
| $539K | 0.05% |
+24,065
| New | +$606K |
|
|
APLS
417
DELISTED
Apellis Pharmaceuticals
APLS
| $539K | 0.05% |
+31,139
| New | +$576K |
|
418
FMC
FMC
$1.33B
| $538K | 0.05% |
12,897
-4,916
| -28% | -$195K |
|
419
AXIS Capital
AXS
$7.55B
| $533K | 0.05% |
5,137
+2,711
| +112% | +$270K |
|
420
Columbia Banking Systems
COLB
$8.84B
| $533K | 0.05% |
22,789
+10,789
| +90% | +$250K |
|
421
Loews
L
$23.6B
| $532K | 0.05% |
+5,805
| New | +$509K |
|
422
iShares MSCI Brazil Small-Cap ETF
EWZS
$221M
| $530K | 0.05% |
40,000
| – | – |
|
423
MSCI
MSCI
$40.9B
| $529K | 0.05% |
917
-283
| -24% | -$157K |
|
424
Coinbase
COIN
$40.5B
| $528K | 0.05% |
1,506
-10,289
| -87% | -$2.41M |
|
425
iShares MSCI Taiwan ETF
EWT
$11.1B
| $527K | 0.05% |
+9,187
| New | +$470K |
|
Similar funds
PFBT
CCP
SP
HCS
SPC
GPCM
MCM
CC
Prelude Capital Management's Q2 2025 Portfolio in Review
As of Q2 2025, Prelude Capital Management held 1,478 positions worth $1.03B, down 22% from $1.32B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Prelude Capital Management withdrew a net $398M in Q2 2025, closing 503 positions and reducing 346 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $10.4M position sold in full.
By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Prelude Capital Management opened a new position in Alphabet (Google) Class C worth $11.7M.
- Prelude Capital Management's largest Q2 2025 buy was Alphabet (Google) Class C: 65,723 shares worth $11.7M.
- Prelude Capital Management added most to Meta Platforms (Facebook) in Q2 2025, an estimated $12.3M increase.
- Prelude Capital Management's biggest Q2 2025 reduction was Broadcom, cutting an estimated $9.33M.
- Prelude Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $10.4M.
- Prelude Capital Management's ten largest holdings make up 14% of its $1.03B portfolio in Q2 2025.
- Prelude Capital Management opened 335 new positions and closed 503 in Q2 2025.
- Prelude Capital Management's portfolio value fell 22% quarter-over-quarter to $1.03B.
Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.